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Objective. We examined the diagnostic value of subjective memory complaints (SMCs) assessed with a single item in a large cross-
sectional cohort consisting of families with autosomal dominant Alzheimer’s disease (ADAD) participating in the Dominantly
Inherited Alzheimer Network (DIAN). Methods. The baseline sample of 183 mutation carriers (MCs) and 117 noncarriers (NCs)
was divided according to Clinical Dementia Rating (CDR) scale into preclinical (CDR 0; MCs: 𝑛 = 107; NCs: 𝑛 = 109), early
symptomatic (CDR 0.5; MCs: 𝑛 = 48; NCs: 𝑛 = 8), and dementia stage (CDR ≥ 1; MCs: 𝑛 = 28; NCs: 𝑛 = 0). These groups were
subdivided by the presence or absence of SMCs. Results. At CDR 0, SMCs were present in 12.1% of MCs and 9.2% of NCs (𝑃 = 0.6).
At CDR 0.5, SMCs were present in 66.7% of MCs and 62.5% of NCs (𝑃 = 1.0). At CDR ≥ 1, SMCs were present in 96.4% of MCs.
SMCs inMCs were significantly associated with CDR, logical memory scores, Geriatric Depression Scale, education, and estimated
years to onset. Conclusions. The present study shows that SMCs assessed by a single-item scale have no diagnostic value to identify
preclinical ADAD in asymptomatic individuals.These results demonstrate the need of further improvement of SMCmeasures that
should be examined in large clinical trials.
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1. Introduction
Alzheimer’s disease (AD) is currently conceptualized as
progressing in three stages including (1) preclinical AD, (2)
early symptomatic AD that has been characterized as mild
cognitive impairment (MCI) due to AD, and (3) dementia
due to AD [1]. After publication of these research criteria
in 2011, the research focus has moved to the preclinical
stage, as it is considered a highly promising target for future
early intervention [2]. Thus, identification of early symptoms
characterizing the preclinical stage of AD is highly needed.
Although interest is increasing in subjective memory
complaints (SMCs), it remains uncertain due to controversial
findings whether they are meaningful or not with respect
to the diagnosis of preclinical sporadic AD. Some studies
have found that SMCs are associated with an increased risk
of developing AD [3, 4], while other studies have found
that they are not predictive of cognitive impairment or
future cognitive decline [5–7] and may correlate better with
depressive symptoms than with cognitive symptoms [8–11].
The terms “subjectivememory/cognitive complaints/decline”
have been used in different ways throughout the last 40
years. In earlier years, “subjective” meant “reporting memory
concerns by the subject in any stage of cognitive impairment”
[12–16]. In most current literature, the term “subjective
cognitive decline” is used for defining a state in the preclinical
stage of sporadic AD and “subjective” means “in absence
of objective impairment” [17]. In the present study, we use
the term SMC because individuals are asked concerning
their memory decline and not concerning other cognitive
functions. In principle, the term SMC can be used at
different stages of cognitive impairment, as done in the
present study, as far as in which stage it is examined is
defined (e.g., “SMC in preclinical AD,” “SMC in MCI,” or
“SMC in dementia”).
Autosomal dominant AD (ADAD) is a rare form of
AD, caused by mutations in genes encoding presenilin-1
(PSEN1), presenilin-2 (PSEN2), or amyloid precursor protein
(APP) and leading to young onset dementia. The oppor-
tunity to observe trajectories of changes in biological and
psychological parameters of dementia-related processes is
explored by the Dominantly Inherited Alzheimer Network
(DIAN), studying ADAD in a large sample of pedigrees with
early onset forms of dementia. Baseline characteristics and
biomarker findings in this cohort are on record [18, 19]. A
previous study with carriers of the PSEN1 E280A mutation
identified a pre-MCI stage with already existing memory
complaints [20]. However, this study focused on mutation
carriers (MCs) and did not describe the frequency of SMCs
in noncarriers (NCs) and the diagnostic value of SMCs in the
different stages of ADAD.
At present the diagnostic value of SMCs in the different
stages of ADAD is unclear. The aim of the current study was
to address this open question by examining the frequency
and diagnostic accuracy of SMCs in MCs and NCs of ADAD
participating in the DIAN study in different clinical stages.
2. Materials and Methods
All aspects of the study were approved by the institutional
review boards for each of the participating sites in DIAN. All
participants provided written informed consent.
2.1. Participants. Thebaseline sample of 183MCs and 117NCs
participants (first-degree relatives ofMCs) of the DIAN study
underwent clinical assessment of cognitive status bymeans of
the Clinical Dementia Rating (CDR) scale [21, 22] and was
consecutively divided into preclinical (asymptomatic; CDR
0), early symptomatic (CDR 0.5), and dementia (CDR ≥ 1)
groups. Only MCs but not NCs fulfilled the criterion of CDR
≥ 1. Thus, CDR ≥ 0.5 refers to the combination of CDR
groups 0.5 and higher for the MCs compared to the CDR
0.5 NCs. Tables 1 and 2 show their demographic data. SMCs
were assessed on FormB9 (Clinician Judgment of Symptoms:
“Does the subject report a decline in memory?”) of the
National Alzheimer’s Coordinating Center (NACC) Uniform
Data Set (UDS) [23]. The groups were subdivided by the
presence or absence of SMCs. Estimated years to onset (EYO)
were calculated as the age of the participant at assessment
minus the age of the parent at symptom onset. EYOwas given
minus values in case of the years before estimated disease
onset and plus values in case of the years after estimated
disease onset. As all participants of the DIAN study are
members of affected ADAD families, the construct of EYO
canbe applied to all (MCs andNCs), resulting in age-matched
cases and controls. This construct of EYO has been validated
in the DIAN study as providing a highly predictable clinical
estimate of stage of AD biomarker profiles and symptom
onset [18].When the study was started, approximately 85% of
participants did not know their mutation status.This recently
has changed over the past one to two years with more partic-
ipants having genetic counseling and testing. We estimated
up to 40% now knowing their genetic status. However, the
information which participant knows the mutation status is
not available in the present database.
2.2. Measurement Methods. All demographical (age, gender,
education, and estimated years to onset [EYO]), clinical
(Geriatric Depression Scale [GDS]), and cognitive measure-
ments (e.g., CDR global scores and sum of boxes [21, 22],
logical memory subtest of The Wechsler Memory Test) were
performed as recently described [18, 19].
2.3. Data Analysis. Subject characteristics were summarized
asmean and standard deviation (SD) for continuous variables
or number for categorical variables. Comparisons between
the MCs and NCs on these characteristics were made with
independent Mann-Whitney 𝑈 tests or Chi-squared tests,
respectively, Fisher’s exact test in case of small expected cell
counts (less than 5). The analyses of the overall association
between memory complaints and CDR groups were per-
formed using the Cochran-Armitage exact trend test, with
Cramer’s 𝑉 used to gauge the relative magnitude of the
association. For determination of diagnostic accuracy, we
calculated the following characteristic numbers: accuracy,
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Table 1: Characteristics of the participants of the DIAN study.
Variables Mutation carriers (MCs)
(𝑁 = 183)
Noncarriers (NCs)
(𝑁 = 117)
𝑃 value
Age (years) 39.1 ± 10.2 39.6 ± 10.3 0.6771∗
Gender (M/F) 81/102 47/70 0.485∗∗
Education level (years) 13.9 ± 2.7 14.6 ± 2.7 0.0343∗
CDR global 0.3 ± 0.6 0.03 ± 0.1 <0.0001∗
CDR sum of boxes 1.64 ± 3.2 0.1 ± 0.2 <0.0001∗
CDR 0 (number) 107 109 0.892∗∗
CDR 0.5 (number) 48 8 <0.0001∗∗
CDR ≥ 1 (number) 28 0 n.a.
Logical memory, delayed recall (percentile) 38.5 ± 36.8 60.9 ± 31.8 <0.0001∗
MMSE 26.8 ± 7.5 29.03 ± 1.3 <0.0001∗
GDS 3.8 ± 11.2 1.3 ± 1.6 <0.0001∗
∗Mann-Whitney𝑈 test; ∗∗Chi-square test; CDR denotes Clinical Dementia Rating Scale; M denotes male and F denotes female; MMSE denotes Mini-Mental
Status Examination; GDS denotes Geriatric Depression Scale; age, education levels, CDR sum of boxes, MMSE, logical memory, and GDS scores are displayed
in mean and standard deviation.
sensitivity, specificity, positive predictive value (PPV), and
negative predictive value (NPV). Significance for the results
was set at 𝑃 < 0.05. All statistical analyses were performed
using SAS 9.3 (SAS Institute, Inc., Cary, NC).
3. Results
3.1. Demographics of Participants of the DIAN Study. MCs
andNCswere comparable regarding age and gender, showing
no significant differences (Table 1). In addition, MCs had
significantly lower educational levels, MMSE, and logical
memory scores and higher CDR global scores, CDR sum
of boxes, and GDS scores than their sibling NCs (Table 1).
Table 2 shows the characteristics of the participants of the
DIAN study by CDR stage and carrier status. A comparison
of the characteristics of the noncarriers (NCs) with CDR 0
versus CDR 0.5 is displayed in Table 3.
3.2. Percentage and Diagnostic Accuracy of SMCs in Partici-
pants of theDIAN StudyDepending onClinical Stage. AtCDR
0, SMCs were present in 12.1% of MCs and 9.2% of NCs (Chi-
square test: 𝑃 = 0.478). At CDR 0.5, SMCs were present in
66.7% ofMCs and 62.5% of NCs (Fisher’s exact test: 𝑃 = 1.0).
At CDR ≥1, SMCs were present in 96.4% of MCs (Figure 1).
Diagnostic accuracy of SMCs for being a MC at CDR 0
was 51.9% (sensitivity 12.2%, specificity 90.8%, PPV 56.5%,
and NPV 51.3%), at CDR 0.5 62.5% (sensitivity 66.7%,
specificity 37.5%, PPV 86.5%, and NPV 15.8%), and at CDR
≥ 0.5 (referring to the combination of CDR groups 0.5 and
higher for the MCs compared to the CDR 0.5 NCs) 73.8%
(sensitivity 77.6%, specificity 37.5%, PPV 92.2%, and NPV
15.0%).
3.3. Association between SMCs and Clinical Parameters in Par-
ticipants of the DIAN Study. SMCs were positively correlated
with CDR stages in MCs (Cramer’s 𝑉 = 0.687; trend test
𝑃 < 0.0001) and in NCs (Cramer’s 𝑉 = 0.403; trend test 𝑃 =
0
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Figure 1: Percentage of mutation carriers (MCs) and noncarriers
(NCs) with subjective memory complaints (SMCs) as a function of
Clinical Dementia Rating (CDR) scale.
0.0008). SMCs were inversely correlated with logical memory
scores in MCs (Cramer’s 𝑉 = −0.541; trend test 𝑃 < 0.0001)
but not in NCs (Cramer’s 𝑉 = −0.154; trend test 𝑃 = 0.098).
In addition, SMCs were positively correlated with EYO in
MCs (Cramer’s 𝑉 = 0.609; trend test 𝑃 < 0.0001), meaning
that MCs with EYO <0 who were closer to onset (less years
to onset) or MCs with EYO ≥0 who were farther from onset
had a higher likelihood of SMCs but not in NCs (Cramer’s
𝑉 = 0.370; trend test 𝑃 = 0.5809). Furthermore, SMCs were
significantly inversely related to education in the cohort as a
whole (Cramer’s 𝑉 = −0.175; trend test 𝑃 = 0.0005) and in
MCs (Cramer’s𝑉 = −0.1352; trend test 𝑃 = 0.0248) and NCs
(Cramer’s 𝑉 = −0.2241; trend test 𝑃 = 0.0341) separately.
Moreover, SMCs were positively correlated with GDS scores
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Table 2: Characteristics of the participants of the DIAN study by CDR stage and carrier status.
Variables Mutation carriers (MCs)(𝑁 = 183)
Noncarriers (NCs)
(𝑁 = 117) 𝑃 value
CDR 0
Age (years) 35.1 ± 8.8 39.4 ± 10.2 0.002∗
Gender (M/F) 46/61 45/64 0.800∗∗
Education level (years) 14.2 ± 2.7 14.7 ± 2.7 0.092∗
CDR sum of boxes 0.03 ± 0.1 0.01 ± 0.08 0.186∗
Logical memory, delayed recall (percentile) 55.3 ± 33.2 62.2 ± 31.1 0.181∗
MMSE 29.0 ± 1.3 29.1 ± 1.3 0.488∗
GDS 1.6 ± 1.9 1.2 ± 1.5 0.129∗
SMCs (number) 13 10 0.478∗∗
CDR 0.5
Age (years) 42.6 ± 9.3 42.4 ± 12.4 0.774∗
Gender (M/F) 21/27 2/6 0.449∗∗∗
Education level (years) 13.4 ± 2.3 12.5 ± 3.4 0.50∗
CDR sum of boxes 1.5 ± 1.1 0.6 ± 0.4 0.007∗
Logical memory, delayed recall (percentile) 17.4 ± 27.6 44.8 ± 39.4 0.015∗
MMSE 26.6 ± 2.8 28.4 ± 1.6 0.09∗
GDS 3.7 ± 3.4 2.1 ± 2.5 0.198∗
SMCs (number) 32 5 1.000∗∗∗
CDR ≥ 1
Age (years) 48.4 ± 8.6 n.a.
Gender (M/F) 14/14 0
Education level (years) 12.8 ± 2.7 n.a.
CDR sum of boxes 7.9 ± 4.1 n.a.
Logical memory, delayed recall (percentile) 10.4 ± 27.1 n.a.
MMSE 15.6 ± 6.3 n.a.
GDS 4.1 ± 3.1 n.a.
SMCs (number) 27 0
∗Mann-Whitney𝑈 test; ∗∗Chi-square test; ∗∗∗Fisher’s exact test; CDR denotes Clinical Dementia Rating Scale; M denotes male and F denotes female; MMSE
denotes Mini-Mental Status Examination; GDS denotes Geriatric Depression Scale; age, education levels, CDR sum of boxes, MMSE, logical memory, and
GDS scores are displayed in mean and standard deviation.
in MCs (Cramer’s 𝑉 = 0.394; trend test 𝑃 < 0.0001) and in
NCs (Cramer’s 𝑉 = 0.197; trend test 𝑃 = 0.033).
Using Spearman partial correlation, we found that SMCs
in MCs were significantly correlated with logical memory
scores even after controlling for GDS scores (𝑟 = −0.396; 𝑃 <
0.0001). In NCs, SMCs showed a trend towards significance
with logical memory after controlling for GDS (𝑟 = −0.179;
𝑃 = 0.055).
Using linear mixed models, MCs with SMCs showed
significantly lower logical memory scores than MCs without
SMCs at CDR 0.5 (Mean ± Standard Error: 5.1 ± 0.8 versus 9.8
± 1.1; 𝑃 = 0.001) and at CDR ≥ 0.5 (8.3 ± 2.8 versus 9.2 ± 1.2;
𝑃 < 0.0001) and a trend of significance at CDR 0 (10.9 ± 1.1
versus 13.3 ± 0.5; 𝑃 = 0.066). In addition, MCs with SMCs
showed significantly higher GDS scores than MCs without
SMCs at CDR 0.5 (Mean ± Standard Error: 4.4 ± 0.7 versus
2.3 ± 0.6; 𝑃 = 0.001) and at CDR ≥ 0.5 (8.4 ± 2.5 versus 2.2 ±
0.5; 𝑃 < 0.0001) and a trend of significance at CDR 0 (2.3 ±
0.8 versus 1.5 ± 0.2; 𝑃 = 0.083).
4. Discussion
The main findings of the present study were as follows. (1)
Preclinical (asymptomatic) MCs of ADAD did not more
frequently report SMCs in comparison with asymptomatic
NCs. (2)The percentage and diagnostic accuracy of SMCs for
being a MC increased with advancing cognitive impairment.
(3) In MCs, SMCs were significantly positively associated
with CDR, GDS, and EYO and inversely with education and
logical memory scores.
In most current literature, the term “subjective cognitive
decline” is used for defining a state in the preclinical stage
of sporadic AD without objective cognitive impairment [17].
However, in the present study, the percentage of asymp-
tomatic individuals with SMCs was rather low (≤12.1%)
and did not differ between MCs and NCs. Thus, SMCs in
asymptomatic members of ADAD families did not segregate
with mutation status. This finding is in line with previous
studies, showing that SMCs are not predictive of cognitive
BioMed Research International 5
Table 3: Comparison of the characteristics of the noncarriers (NCs) with CDR 0 versus CDR 0.5.
Variables Noncarriers (NCs) CDR 0(𝑁 = 109)
Noncarriers (NCs) CDR 0.5
(𝑁 = 8) 𝑃 value
Age (years) 39.4 ± 10.2 42.4 ± 12.4 0.552∗
Gender (M/F) 45/64 2/6 0.427∗∗
Education level (years) 14.7 ± 2.7 12.5 ± 3.4 0.068∗
CDR sum of boxes 0.01 ± 0.08 0.6 ± 0.4 <0.0001∗
Logical memory, delayed recall (percentile) 62.2 ± 31.1 44.8 ± 39.4 0.257∗
MMSE 29.1 ± 1.3 28.4 ± 1.6 0.125∗
GDS 1.2 ± 1.5 2.1 ± 2.5 0.285∗
SMCs (number) 10 5 0.001∗∗
∗Mann-Whitney𝑈 test; ∗∗Fisher’s exact test; CDR denotes Clinical Dementia Rating Scale;M denotesmale and F denotes female; MMSE denotesMini-Mental
Status Examination; GDS denotes Geriatric Depression Scale; age, education levels, CDR sum of boxes, MMSE, logical memory, and GDS scores are displayed
in mean and standard deviation.
impairment or future cognitive decline [5–7]. A previous
study with carriers of the PSEN1 E280A mutation identi-
fied a pre-MCI stage, characterized by memory complaints
and coexisting objective cognitive impairment [20]. These
findings indicate that SMCs in ADAD seem to occur rarely
without additional objective cognitive impairment which is
different from what is expected in sporadic AD [17]. This
potential difference between ADAD and sporadic AD could
be explained by a more aggressive course of ADAD [24] with
an earlier onset of objective cognitive impairment and thus
with a shorter asymptomatic phase.
The relevance of assessing SMCs is not restricted to
preclinical AD, as nonspecialists in primary care are inac-
curate at identifying dementia as well as MCI [25]. In the
present study, frequency of SMCs clearly increased during the
course of ADADalongwith advancing cognitive impairment.
According to a meta-analysis, SMCs were reported by 38%
of those with known MCI and 43% of those with known
dementia [16]. The higher percentage of SMCs in individuals
with early symptomatic ADAD (66.7%) and dementia due to
ADAD (96.4%) in the present study could be explained by
the fact that members of families affected with ADAD may
be more aware of or vigilant towards the cognitive changes
than individuals in the general population. Additionally,
the ADAD individuals are usually younger than those with
late onset MCI/AD and therefore, any cognitive decline is
more readily noticed without being ascribed to “age-related”
limitations that can commonly be seen in older adults.
In the present study, 9.2% of asymptomatic NCs reported
SMCs. This result is not surprising as in a recent study
14.4% of young adults (aged 18–39 years) reported SMCs [26].
Interestingly, 8/117 NCs showed in the present study a CDR of
0.5. Comparing the baseline characteristics in NCs with CDR
0.5 versus NCs with CDR 0 revealed that NCs with CDR 0.5
also showed higher CDR sum of boxes scores, a higher rate of
SMCs, and a trend of lower education level compared to NCs
with CDR 0.
Several previous studies have demonstrated a relationship
between SMCs and depressivemood states [8–11]. In linewith
these findings, we also found positive correlations between
SMCs and GDS scores in MCs and NCs. In addition, MCs
with SMCs showed significantly higherGDS scores thanMCs
without SMCs at CDR 0.5 and at CDR ≥ 0.5 and a trend of
significance at CDR 0. However, the significant relationship
between SMCs and GDS does not rule out an ongoing
neurodegenerative process or cognitive deterioration. We
reported a significant association between SMCs, cognitive
function (as measured by the logical memory subtest of the
Wechsler Memory Test), and cognitive impairments (CDR
results) as well as higher memory difficulties in MCs with
SMCs. Interestingly, inMCs, we reported a significant associ-
ation between subjective and objective measures of memory,
even after controlling for depression effects (as measured
using GDS). This significant association was not observed
for NCs after controlling for depression score. These findings
signify the sensitivity of SMCs to cognitive changes due to
neurodegenerative processes of AD while their specificity
requires further investigations.
A limitation of the study was that SMCs were captured
by use of a single question with a binary threshold based on
clinician judgement, which may be not sensitive enough to
detect more subtle self-perceived changes. However, using a
single-item question on SMCs has been previously reported
to predict late onset AD incidence [3]. Another limitationwas
that the question concerning SMCs specifically referred to
memory and did not include decline in behaviour, motor, or
other cognitive functions. Furthermore, the number of indi-
viduals with SMCs in the preclinical stage of AD was rather
small. In addition, the data analyzed were cross-sectional
baseline data of the DIAN study, with limited predictive
power concerning the EYO as opposed to individual longitu-
dinal data. However, no sufficient longitudinal data are as yet
available. It should also be noted that due to younger age, clin-
ical observations resulted from studying ADAD may not be
directly transferable to those in sporadic AD and vice versa.
5. Conclusions
Data of the present study indicate that SMCs assessed by
a single-item scale have no diagnostic value to identify
preclinical ADAD in asymptomatic individuals.These results
demonstrate the need of further improvement of SMC
6 BioMed Research International
assessment (at least in the ADAD population), for example,
by additional use of multi-items and quantitative measures
of SMCs. Additionally, multidomain cognitive complaint
measures and inclusion of the informant part may increase
the clinical utility of this construct. The diagnostic and
clinical value of different SMC test instruments should be
examined now in larger clinical trials with sporadic AD
patients. The significant relationship of SMCs with logical
memory and dementia stages, as we reported here, warrants
further investigation into its clinical applications in general
practice within elderly population.
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